Skip Navigation LinksHome > November 2013 - Volume 21 - Issue 6 > Virological Response to Standard- and Double-Dose Oseltamivi...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31828bbb66
Original Articles

Virological Response to Standard- and Double-Dose Oseltamivir Treatment in Patients With Pandemic (H1N1) 2009 Influenza: A Prospective Randomized Trial

Durigon, Edison L. PhD*; Thomazelli, Luciano M. PhD*; Oliveira, Danielle B.L. PhD*; Macedo, Priscila V. BSc*; Lotufo, João P.B. MSc; da Cunha, Clóvis A. MD; Neto, João T. PhD§

Collapse Box


Background: In the early stages of the 2009 influenza pandemic, little was known about the pandemic (H1N1) 2009 virus or its response to neuraminidase inhibitor therapy.

Methods: Between April 2009 and August 2010, we conducted an open-label study of the response to oseltamivir therapy when administered at the recommended dose or at double the recommended dose twice daily for 5 days.

Results: Thirty-eight patients aged 5 years or older with laboratory-confirmed pandemic (H1N1) 2009 influenza were randomly assigned to treatment. After 5 days, substantial reductions in viral load and clinical signs and symptoms of influenza were observed in the standard- and double-dose groups relative to baseline values. The double-dose regimen did not provide additional benefit over the standard-dose regimen. No resistant viruses were detected. Both regimens were well tolerated, and no serious adverse events were reported.

Conclusions: Standard- and double-dose oseltamivir regimens were well tolerated in this patient group.

© 2013 by Lippincott Williams & Wilkins.

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.